Gene Variants and Prostate Cancer Risk in Men with Benign Prostate Hyperplasia
Author Information
Author(s): Tayeb M T, Clark C, Haites N E, Sharp L, Murray G I, McLeod H L
Primary Institution: University of Aberdeen
Hypothesis
Are CYP3A4 and VDR gene polymorphisms associated with an increased risk of prostate cancer in men with benign prostate hyperplasia?
Conclusion
The study found that certain genetic variants are associated with a higher risk of developing prostate cancer in men with benign prostate hyperplasia.
Supporting Evidence
- The study found that the CYP3A4*1B allele was associated with a higher clinical stage and grade of prostate cancer.
- BPH patients with the CYP3A4*1B and VDR TT combined genotypes had a 13-fold higher risk of developing prostate cancer.
- The incidence rate of prostate cancer was higher in BPH patients with the CYP3A4*1B genotype compared to those with the CYP3A4*1A genotype.
Takeaway
This study looked at how certain genes might make men with prostate enlargement more likely to get prostate cancer. They found that some gene changes can increase this risk.
Methodology
The study analyzed genetic data from 400 benign prostatic hyperplasia patients to determine the association between specific gene variants and prostate cancer risk.
Limitations
The study's power to detect significant associations was limited, and results did not reach statistical significance.
Participant Demographics
The study included men with benign prostatic hyperplasia from Northeast Scotland.
Statistical Information
Confidence Interval
95% CI=0.999–11.770
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website